… open-label, phase 3 randomised controlled trial at 183 cancer centres in 23 countries
worldwide. We enrolled adults with stage IIIB or IV squamous cell carcinoma of the lung who had …

… This article reports detailed analysis of PROs from LUX-Lung 3. … in the LUX-Lung 3 study
was also associated with significantly better control of two of the three prespecified lung cancer–…

… This multicentre, international, open-label, exploratory, randomised controlled phase 2B
trial (LUX-Lung 7) was done at 64 centres in 13 countries. Treatment-naive patients with stage …

… Here, we report mature overall survival results from the individual LUX-Lung 3 and LUX-Lung
6 studies. Additionally, to provide more accurate estimates of the overall effect of afatinib …

… In LUX-Lung 6, A was significantly better than … : In LUX-Lung 6, prolongation of PFS with A
was associated with significantly better HRQoL and significantly longer control of lung cancer-…

… A was superior to first-line pemetrexed/cisplatin in a global phase III trial (LUX-Lung 3) in
EGFR M+ NSCLC. This study compared the safety and efficacy of first-line A with GC in EGFR M…

… In this phase 2 study, we enrolled patients from 30 centres in Taiwan and the USA with lung
adenocarcinoma (stage IIIb with pleural effusion or stage IV) with EGFR mutations, who had …

… -Lung 4 trial with prior failure of erlotinib and/or gefitinib and an enrichment strategy for …
patients shown in LUX-Lung 1. In the LUX-Lung 1 double-blind, placebo-controlled phase IIB/III …

7521^ Background: NSCLC patients whose tumors harbor epidermal growth factor receptor
EGFR/HER1 mutations represent a unique subpopulation with unparalleled responsiveness …

… LUX-Lung 8 was a randomised, controlled, phase 3 study comparing afatinib and erlotinib
as second-line treatment of patients with advanced squamous cell carcinoma (SCC) of …